COPENHAGEN, Denmark — October 3, 2025 — Leads & Copy — Evaxion A/S (NASDAQ: EVAX) will present new data for its lead asset EVX-01 at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting in National Harbor November 5-9, 2025. The company will also present two-year clinical efficacy data from the trial at the European Society for Medical Oncology (ESMO) 2025 congress on October 17, 2025.
The data will be the latest of many additions to EVX-01’s strong data package. Designed with Evaxion’s AI-Immunology™ platform, EVX-01 is a personalized cancer vaccine currently being evaluated as a treatment for advanced melanoma (skin cancer).
The phase 2 trial investigates EVX-01 in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with advanced melanoma (skin cancer). Each patient enrolled in the trial has received a unique vaccine designed and manufactured based on their individual biology.
SITC presentation details: Abstract title: Immune correlates of clinical response following treatment with the personalized cancer vaccine EVX-01 and Pembrolizumab in advanced melanoma patients; Abstract#: 605; Poster#: 605; Session (category): Clinical trials in progress (subcategory: Skin cancers); Location: Lower Level Atrium – Prince George’s ABC; Date/Time: Friday, November 7, 2025, 5:10–6:35 p.m. ET/23.10-00.35 CET; Presenter: Michail Angelos Pavlidis, Research Associate at Evaxion
EVX-01 is a personalized peptide-based cancer vaccine intended for first-line treatment of multiple advanced solid cancers. In clinical trials, EVX-01 has demonstrated 69% and 67% Overall Response Rates in patients with advanced melanoma.
Mads Kronborg, Vice President, Investor Relations & Communication, +45 53 54 82 96, mak@evaxion.ai
Source: Evaxion A/S
